Susquehanna International Group, LLP Humacyte, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$5.11 - $9.46 $1.07 Million - $1.97 Million	-208,500 Reduced 76.4%	64,400 $350,000
Q2 2024 Aug 15, 2024	BUY	$2.87 - $9.1 $783,223 - $2.48 Million	272,900 New	272,900 $1.31 Million
Q3 2022 Nov 14, 2022	BUY	$1.22 - $5.14 $35,258 - $148,546	28,900 Added 140.98%	49,400 $161,000
Q2 2022 Aug 15, 2022	SELL	$3.21 - $7.86 $99,189 - $242,874	-30,900 Reduced 60.12%	20,500 $66,000
Q1 2022 May 16, 2022	SELL	$4.65 - $7.4 $712,845 - $1.13 Million	-153,300 Reduced 74.89%	51,400 $363,000
Q4 2021 Feb 14, 2022	SELL	$7.25 - $11.6 $1.01 Million - $1.62 Million	-139,600 Reduced 40.55%	204,700 $1.48 Million
Q3 2021 Nov 15, 2021	BUY	$9.21 - $16.99 $3.17 Million - $5.85 Million	344,300 New	344,300 $4 Million

150

35.1M

279K

607K

Ticker HUMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,007,000
Market Cap $499M
Description
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.